Oslo, 24 January 2020 - Navamedic ASA (OSE: NAVA), today announces it has
entered into an agreement with Alimentary Health for the launch of Alflorex®, a
unique product for irritable bowel syndrome (IBS), in the Netherlands in 2H
2020. In December 2019, Navamedic launched Alflorex® in Denmark. 

"We are pleased to announce the agreement with Alimentary Health, expanding our
distribution of Alflorex® to the Netherlands, a key growth market for Navamedic.
About 10-15% of the population have IBS symptoms, and by introducing Alflorex®
in more markets we are contributing to improved quality of life by helping IBS
sufferers to take back control of their gut health," says Kathrine Gamborg
Andreassen, CEO of Navamedic. 

Based on a strategic partnership with PrecisionBiotics Ltd, Navamedic is already
distributing Alflorex® to pharmacies in Norway and in December 2019, the company
launched the product in pharmacies in Denmark. In addition, Navamedic has the
territory rights to launch the product in Iceland. 

"Expansion of existing products to new geographies proves the attractiveness of
Navamedic's highly scalable market access platform, and is a recognition of our
expertise in introducing, positioning and marketing of products across
categories. Both the consumer health gastro therapeutic area and the probiotic
market is underdeveloped in our markets, and we aim to drive growth in this
market with this unique product," says Gamborg Andreassen.

Alimentary Health is the owner of Alflorex® and part of the PrecisionBiotics
Group, who is developing unique bacteria cultures that have been specifically
researched and rigorously tested for specific indications. 

Alflorex® for IBS is classified as a medical Class IIb and contains the patented
bacterial strain, Bifidobacterium Longum 35624®. The 35624® bacteria culture is
clinically proven to reduce symptoms for IBS, including bloating and gas,
abdominal pain, diarrhea and constipation. 

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680 
E-mail: kathrine@navamedic.com 

Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange